Research programme: pseudomonas vaccine - GenVec

Drug Profile

Research programme: pseudomonas vaccine - GenVec

Alternative Names: AdOprF.RGD.Epi8 - GenVec

Latest Information Update: 29 Jun 2017

Price : $50

At a glance

  • Originator GenVec
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections

Most Recent Events

  • 16 Jun 2017 GenVec has been acquired by Intrexon Corporation
  • 24 Jun 2005 Preclinical trials in Cystic fibrosis-associated respiratory tract infections in USA (unspecified route)
  • 24 Jun 2005 Preclinical trials in Pseudomonal infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top